HEMOSTASIS COAGULATION ROUTINE REAGENTS INHIBITOR NIJMEGEN BETHESDA ASSAYS FVIII INHIBITOR NIJMEGEN BETHESDA CONTROLS
Factor VIII Inhibitor Plasma Weak Control
Factor VIII deficient plasma without Factor VIII inhibitor.
This plasma can be used for the control of the determination of Factor VIII (FVIII) inhibitor according to the Bethesda assays or modified Nijmegen Bethesda assays.
Factor VIII Inhibitor Plasma Weak Control is made from a pool of Factor VIII deficient (<1%) human plasma.
It contains a specific natural inhibitor directed against the activity of Factor VIII (FVIII).
Informations
Treatment for hemophilia A consists of injecting the missing factor VIII I.V. to prevent or stop bleeding. A majority of the complications of this treatment are the development of antibodies against FVIII, called inhibitors.
The development of an anti-FVIII inhibitor leads to episodes of bleeding that are difficult to control.
The activity of the inhibitor is measured by the Bethesda assays or modified Nijmegen Bethesda and is expressed in BU. 1BU neutralizes 50% of the activity of FVIII for hemophilia A.
Documentation
Download the product sheetPrice list, safety data sheets and notices are accessible to our registered customers.
Nijmegen Bethesda Controls
References
| 6-1800-05 | Vial | 25 x 0.5 mL |
